Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: A prospective comparison of prophylactic versus deferred preemptive lamivudine

Shih Hung Tsai, Ming Shen Dai, Jyh Cherng Yu, Ching Liang Ho, Yeu Chin Chen, Yi Ying Wu, Ping Ying Chang, Woei Yau Kao, Tsu Yi Chao

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose Prophylactic lamivudine to prevent chemotherapyinduced hepatitis B virus (HBV) reactivation has been widely adopted in hematological cancer patients. We examined the deferred preemptive strategy, upon rising viremia, in breast cancer (BC) patients based on sensitive serum HBV DNA level monitoring in a non-randomized controlled study. Patients and methods Baseline virological profiles before cytotoxic chemotherapy were retrospectively analyzed in historical BC and non-BC patients. A prospective cohort study, including 22 early BC patients (Group I) who were hepatitis B surface antigen (HBsAg)± and required adjuvant chemotherapy, were enrolled and had deferred preemptive use of lamivudine upon viremic surge. During the study period, another 23 BC patients, who did not participate in the abovementioned study, received prophylactic use of lamivudine as routine practice (Group 2). Chemotherapyinduced hepatitis events and the lamivudine treatment course were compared. Results There was no significant difference in the incidence of hepatitis during chemotherapy between these two groups. Patients in Group I had statistically significant shorter duration of lamivudine use during chemotherapy. However, once lamivudine had been initiated, the treatment course is not significantly shorter than those patients given prophylactically. Conclusions Deferred preemptive strategy is feasible to control HBV replication and prevent its reactivation in BC patients undergoing chemotherapy. However, it may not be superior to prophylactic strategy and clinically practical.

Original languageEnglish
Pages (from-to)1779-1787
Number of pages9
JournalSupportive Care in Cancer
Volume19
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Lamivudine
Hepatitis B
Breast Neoplasms
Drug Therapy
Hepatitis B virus
Hepatitis
Viremia
Adjuvant Chemotherapy
Hepatitis B Surface Antigens
Virus Replication
Neoplasms
Cohort Studies
Prospective Studies
DNA
Incidence

Keywords

  • Breast cancer
  • HBV
  • Hepatitis
  • Lamivudine
  • Preemptive

ASJC Scopus subject areas

  • Oncology

Cite this

Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients : A prospective comparison of prophylactic versus deferred preemptive lamivudine. / Tsai, Shih Hung; Dai, Ming Shen; Yu, Jyh Cherng; Ho, Ching Liang; Chen, Yeu Chin; Wu, Yi Ying; Chang, Ping Ying; Kao, Woei Yau; Chao, Tsu Yi.

In: Supportive Care in Cancer, Vol. 19, No. 11, 11.2011, p. 1779-1787.

Research output: Contribution to journalArticle

Tsai, Shih Hung ; Dai, Ming Shen ; Yu, Jyh Cherng ; Ho, Ching Liang ; Chen, Yeu Chin ; Wu, Yi Ying ; Chang, Ping Ying ; Kao, Woei Yau ; Chao, Tsu Yi. / Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients : A prospective comparison of prophylactic versus deferred preemptive lamivudine. In: Supportive Care in Cancer. 2011 ; Vol. 19, No. 11. pp. 1779-1787.
@article{ff1ade703be74e83a3ffcc1dc29a5242,
title = "Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: A prospective comparison of prophylactic versus deferred preemptive lamivudine",
abstract = "Purpose Prophylactic lamivudine to prevent chemotherapyinduced hepatitis B virus (HBV) reactivation has been widely adopted in hematological cancer patients. We examined the deferred preemptive strategy, upon rising viremia, in breast cancer (BC) patients based on sensitive serum HBV DNA level monitoring in a non-randomized controlled study. Patients and methods Baseline virological profiles before cytotoxic chemotherapy were retrospectively analyzed in historical BC and non-BC patients. A prospective cohort study, including 22 early BC patients (Group I) who were hepatitis B surface antigen (HBsAg)± and required adjuvant chemotherapy, were enrolled and had deferred preemptive use of lamivudine upon viremic surge. During the study period, another 23 BC patients, who did not participate in the abovementioned study, received prophylactic use of lamivudine as routine practice (Group 2). Chemotherapyinduced hepatitis events and the lamivudine treatment course were compared. Results There was no significant difference in the incidence of hepatitis during chemotherapy between these two groups. Patients in Group I had statistically significant shorter duration of lamivudine use during chemotherapy. However, once lamivudine had been initiated, the treatment course is not significantly shorter than those patients given prophylactically. Conclusions Deferred preemptive strategy is feasible to control HBV replication and prevent its reactivation in BC patients undergoing chemotherapy. However, it may not be superior to prophylactic strategy and clinically practical.",
keywords = "Breast cancer, HBV, Hepatitis, Lamivudine, Preemptive",
author = "Tsai, {Shih Hung} and Dai, {Ming Shen} and Yu, {Jyh Cherng} and Ho, {Ching Liang} and Chen, {Yeu Chin} and Wu, {Yi Ying} and Chang, {Ping Ying} and Kao, {Woei Yau} and Chao, {Tsu Yi}",
year = "2011",
month = "11",
doi = "10.1007/s00520-010-1019-2",
language = "English",
volume = "19",
pages = "1779--1787",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients

T2 - A prospective comparison of prophylactic versus deferred preemptive lamivudine

AU - Tsai, Shih Hung

AU - Dai, Ming Shen

AU - Yu, Jyh Cherng

AU - Ho, Ching Liang

AU - Chen, Yeu Chin

AU - Wu, Yi Ying

AU - Chang, Ping Ying

AU - Kao, Woei Yau

AU - Chao, Tsu Yi

PY - 2011/11

Y1 - 2011/11

N2 - Purpose Prophylactic lamivudine to prevent chemotherapyinduced hepatitis B virus (HBV) reactivation has been widely adopted in hematological cancer patients. We examined the deferred preemptive strategy, upon rising viremia, in breast cancer (BC) patients based on sensitive serum HBV DNA level monitoring in a non-randomized controlled study. Patients and methods Baseline virological profiles before cytotoxic chemotherapy were retrospectively analyzed in historical BC and non-BC patients. A prospective cohort study, including 22 early BC patients (Group I) who were hepatitis B surface antigen (HBsAg)± and required adjuvant chemotherapy, were enrolled and had deferred preemptive use of lamivudine upon viremic surge. During the study period, another 23 BC patients, who did not participate in the abovementioned study, received prophylactic use of lamivudine as routine practice (Group 2). Chemotherapyinduced hepatitis events and the lamivudine treatment course were compared. Results There was no significant difference in the incidence of hepatitis during chemotherapy between these two groups. Patients in Group I had statistically significant shorter duration of lamivudine use during chemotherapy. However, once lamivudine had been initiated, the treatment course is not significantly shorter than those patients given prophylactically. Conclusions Deferred preemptive strategy is feasible to control HBV replication and prevent its reactivation in BC patients undergoing chemotherapy. However, it may not be superior to prophylactic strategy and clinically practical.

AB - Purpose Prophylactic lamivudine to prevent chemotherapyinduced hepatitis B virus (HBV) reactivation has been widely adopted in hematological cancer patients. We examined the deferred preemptive strategy, upon rising viremia, in breast cancer (BC) patients based on sensitive serum HBV DNA level monitoring in a non-randomized controlled study. Patients and methods Baseline virological profiles before cytotoxic chemotherapy were retrospectively analyzed in historical BC and non-BC patients. A prospective cohort study, including 22 early BC patients (Group I) who were hepatitis B surface antigen (HBsAg)± and required adjuvant chemotherapy, were enrolled and had deferred preemptive use of lamivudine upon viremic surge. During the study period, another 23 BC patients, who did not participate in the abovementioned study, received prophylactic use of lamivudine as routine practice (Group 2). Chemotherapyinduced hepatitis events and the lamivudine treatment course were compared. Results There was no significant difference in the incidence of hepatitis during chemotherapy between these two groups. Patients in Group I had statistically significant shorter duration of lamivudine use during chemotherapy. However, once lamivudine had been initiated, the treatment course is not significantly shorter than those patients given prophylactically. Conclusions Deferred preemptive strategy is feasible to control HBV replication and prevent its reactivation in BC patients undergoing chemotherapy. However, it may not be superior to prophylactic strategy and clinically practical.

KW - Breast cancer

KW - HBV

KW - Hepatitis

KW - Lamivudine

KW - Preemptive

UR - http://www.scopus.com/inward/record.url?scp=83255193533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83255193533&partnerID=8YFLogxK

U2 - 10.1007/s00520-010-1019-2

DO - 10.1007/s00520-010-1019-2

M3 - Article

C2 - 20927554

AN - SCOPUS:83255193533

VL - 19

SP - 1779

EP - 1787

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 11

ER -